| Expression pattern: |
DN |
| Associated gene: |
DHX9, STEAP4, FAK, Ago2 |
| Associated microRNA: |
miR-1265 |
| Biological function: |
inhibits bladder cancer cell migration, invasion, wound healing and lymphatic metastasis; inhibits EMT |
| Molecular mechanism: |
circPICALM acts as a miR-1265 sponge (ceRNA) to regulate STEAP4, thereby affecting FAK autophosphorylation at Y397 and EMT; DHX9 negatively regulates circPICALM levels |
| Biological pathway or process: |
migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Transwell Assay; Wound Healing Assay; Western Blot; Co-IP; In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
low circPICALM expression was related to advanced T stage, high grade, lymph node positivity and poor overall survival; circPICALM expression was an independent prognostic factor |
| Description: |
circPICALM is downregulated in bladder cancer and functions as a metastasis suppressor. It mainly localizes in the cytoplasm and sponges miR-1265 to de-repress STEAP4, thereby reducing FAK Y397 phosphorylation and inhibiting EMT and metastatic behaviors. Low circPICALM is associated with advanced clinicopathologic features and worse overall survival. |
| Confidence score: |
0.895 |